AUG 18, 2026 · PHASE 1 TRIAL
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
ClinicalTrials.gov
First-in-human Phase 1 dose-escalation study with no results posted; designed to establish safety, tolerability, and dose recommendations rather than efficacy.
Reported
Planned enrollment90
PhasePhase 1
Primary outcome measure 1Recommended phase 2 dose (RP2D) and/or maxi…